Loading organizations...
Immunome has raised $12.8M across 3 funding rounds.
Key people at Immunome.
Immunome has raised $12.8M in total across 3 funding rounds.
Immunome is a clinical-stage oncology company dedicated to the discovery and development of targeted therapies, notably antibody-drug conjugates (ADCs). It utilizes a proprietary discovery engine to interrogate the human immune system, focusing on memory B cells to identify novel therapeutic antibodies and their specific targets. This precise approach aims to create highly selective treatments for various cancers.
The company’s scientific foundation originates from the research of Dr. Scott Dessain, its key scientific founder. His insight involved studying memory B cells from cancer patients exhibiting exceptional immune responses. This innovative methodology underpins Immunome’s platform, designed to harness the body’s natural defenses to unearth potent therapeutic candidates.
Immunome develops products for cancer patients, driven by a mission to improve treatment outcomes. The company focuses on delivering a pipeline of first-in-class and best-in-class targeted oncology therapeutics. Its vision centers on translating biological discoveries into innovative medicines that address critical unmet medical needs and elevate cancer care.
Key people at Immunome.
Immunome has raised $12.8M in total across 3 funding rounds.
Immunome's investors include Wistar Morris, BioAdvance.
Immunome has raised $12.8M across 3 funding rounds. Most recently, it raised $12.2M Series A Extension in October 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 10, 2016 | $12.2M Series A Plus | — | — | Announced |
| Feb 27, 2013 | $440K Venture Round | — | — | Announced |
| Jan 31, 2012 | $140K Venture Round | — | Wistar Morris, BioAdvance | Announced |
Immunome, Inc. (NASDAQ: IMNM) is a clinical-stage biotechnology company developing first-in-class and best-in-class targeted cancer therapies, primarily antibody-drug conjugates (ADCs), radioligand therapies (RLTs), and other immunotherapies for oncology indications with high unmet needs.[1][3][6] It leverages proprietary platforms like Artemis™ (formerly RealMab™ and ScreenMab™) to discover novel antibodies and targets from human memory B cells and super-responder patients, addressing undruggable targets in oncology and infectious diseases.[1][2][4] The company serves cancer patients globally through its internal pipeline and potential biopharma partnerships, solving the problem of limited effective treatments for solid tumors by delivering potent anti-cancer agents directly to tumors.[1][2][3] As of early 2025, Immunome shows growth momentum with late-stage assets like varegacestat (AL102) for desmoid tumors, Phase 1 IM-1021 (ROR1 ADC), IND-cleared IM-3050 (FAP RLT), and preclinical ADCs, bolstered by strategic acquisitions like from Zentalis and Atreca.[3][5]
Immunome was founded in 2018, evolving from earlier tumor immunology efforts documented in a 2016 corporate overview under Immunome Corp., which raised an $8.5M Series A to advance platforms isolating fully human antibodies from super-responder patients.[1][4] The company originated from expertise in leveraging the human immune system—specifically RealMab™ (isolating antibodies against patient tumors) and ScreenMab™ (functional screening)—to identify antigen-antibody pairs for ADCs and CAR-T therapies.[4] Key early traction came from building a pipeline of these pairs and rapid team expansion post-Series A.[4] By 2024-2025, Immunome shifted to a clinical-stage focus under experienced leadership with track records in commercializing ADCs for lymphoma and bladder cancer, incorporating acquisitions and IND clearances for multiple programs.[3][5][6]
Immunome stands out in the competitive biotech landscape through:
Immunome rides the ADC and targeted oncology wave, a market exploding due to successes like approved ADCs for lymphoma and bladder cancer, with demand for next-gen therapies addressing solid tumor limitations in existing programs.[3][5][6] Timing aligns with 2025 IND clearances and clinical readouts amid rising investor interest in precision oncology, fueled by advances in linker/payload tech and radioligands.[3][5] Favorable forces include high unmet needs in desmoid tumors/solid cancers, biopharma partnering trends for non-dilutive capital, and Immunome's human immune-derived assets differentiating from synthetic libraries.[1][2][5] It influences the ecosystem by validating underexplored targets, enabling efficient clinical decisions, and contributing to the shift toward target-driven, multimodal oncology tools.[2][5]
Immunome is poised to advance its pipeline toward key 2025-2026 milestones, including Phase 1 data for IM-1021/IM-3050, potential varegacestat approval, and new INDs for IL-38 and preclinical ADCs, while pursuing partnerships to de-risk development.[3][5] Trends like ADC optimization, radioligand expansion, and M&A in oncology will shape its path, potentially scaling influence through commercialization or buyouts in a syndicate-backed model.[2][5] Evolving from discovery to a premier targeted oncology player, Immunome could deliver transformative therapies, tying back to its core mission of harnessing human immunology for patients facing limited options.[1][3]
